The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What data are expected this year within the field of CAR T for multiple myeloma?

Feb 1, 2020

During the 2nd European CAR T Cell Meeting in Sitges, ES, the Multiple Myeloma Hub was delighted to speak to Mohamad Mohty, Saint-Antoine Hospital and Sorbonne University, Paris, FR. We asked: What data are expected this year within the field of CAR T for multiple myeloma?

Mohamad Mohty discusses CAR T-cell therapy in multiple myeloma, he explains that there is an unmet need for treatment, especially in the relapsed/refractory setting. He discusses clinical trials such as CARTITUDE, bb2121, and Legend trials, that evaluated response rates and outcomes in patients with multiple myeloma that were treated with CAR T and explains the results are encouraging.

What data are expected this year within the field of CAR T for multiple myeloma?